Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

VASCULAR DISEASES

A new tale of thalidomide repurposing

Nature Cardiovascular Research volume 1, pages 535–536 (2022)Cite this article

Subjects

A prospective observational case-report study now shows that thalidomide can be a well-tolerated, efficacious treatment for complications such as pain, bleeding and ulceration from extracranial arteriovenous malformation.

Arteriovenous malformations (AVMs) are among the most difficult to treat and dangerous vascular malformations. Effective treatments are urgently needed to prevent life-threatening complications. AVMs are formed by a ‘nidus’ of low-resistance vessels that results in direct shunting of blood from high-flow arteries into veins, without the intervening capillary bed and perfusion of adjacent tissue. The pulsatile flow through weakened vessel walls can lead to severe and sometimes life-threatening complications, including pain, ulceration, hemorrhage, stroke and uncontrolled bleeding. Conventional surgical management of AVMs includes embolization followed by surgical resection. However, the risk of complications such as tissue ischemia and necrosis is high, and recurrence within a year following embolization can be over 90% (ref. 1). Due to neovascularization after surgery, the rebound growth can sometimes be worse than the initial disease.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Uncontrolled endothelial cell proliferation due to activation of multiple signaling pathways results in increased angiogenesis and AVM.

References

  1. Liu, A. S. et al. Plast. Reconstr. Surg. 125, 1185–1194 (2010).

    Article  CAS  Google Scholar 

  2. McDonald, J. & Stevenson, D.A. GeneReviews (eds. Adam, M.P. et al.) (University of Washington, 1993).

  3. Amyere, M. et al. Circulation 136, 1037–1048 (2017).

    Article  CAS  Google Scholar 

  4. Revencu, N. et al. J. Med. Genet. 57, 48–52 (2020).

    Article  CAS  Google Scholar 

  5. Scherschinski, L. et al. World. Neurosurg. 159, 327–337 (2022).

    Article  Google Scholar 

  6. Smits, P. J. et al. Biochem. Biophys. Res. Commun. 529, 450–454 (2020).

    Article  CAS  Google Scholar 

  7. Boon, L. M. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-022-00080-2 (2022).

    Article  Google Scholar 

  8. Invernizzi, R. et al. Lancet Haematol. 2, e465–e473 (2015).

    Article  Google Scholar 

  9. Komorowski, J. et al. Life Sci. 78, 2558–2563 (2006).

    Article  CAS  Google Scholar 

  10. Lekwuttikarn, R. et al. JAMA Dermatol. 155, 256–257 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, USA

    Joyce M. C. Teng & Dawn H. Siegel

Authors
  1. Joyce M. C. Teng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dawn H. Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joyce M. C. Teng.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teng, J.M.C., Siegel, D.H. A new tale of thalidomide repurposing. Nat Cardiovasc Res 1, 535–536 (2022). https://doi.org/10.1038/s44161-022-00087-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-022-00087-9

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research